IRC23 Antibody

What is IRF3 and why is it important in immunological research?

IRF3 (Interferon Regulatory Factor 3) is a 60 kDa transcription factor that plays a critical role in the innate immune response to viral infections. It contains one DNA binding domain (amino acids 7-107), a nuclear export signal (amino acids 139-149), and multiple phosphorylation sites (amino acids 395-407). Upon viral infection, IRF3 becomes phosphorylated, translocates to the nucleus, and stimulates interferon production . The importance of IRF3 in immunological research stems from its central role in antiviral immunity and type I interferon signaling pathways. Studying IRF3 helps researchers understand fundamental aspects of innate immunity and viral defense mechanisms.

What cell types express IRF3 and how can I detect its expression?

IRF3 is broadly expressed across many cell types, with notable expression in immune cells. Flow cytometry is a common method for detecting IRF3 expression. For example, Daudi human Burkitt's lymphoma cell line can be stained with Mouse Anti-Human IRF3 Alexa Fluor® 488-conjugated Monoclonal Antibody to detect IRF3 expression . For intracellular staining, cells must be fixed with Flow Cytometry Fixation Buffer and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I since IRF3 is predominantly intracellular . Western blotting and immunofluorescence microscopy are also effective methods for IRF3 detection in various cell types.

How should IRF3 antibodies be stored and handled to maintain reactivity?

IRF3 antibodies conjugated with fluorophores (such as Alexa Fluor® 488) require specific storage conditions. These antibodies should be stored at 2 to 8°C for up to 12 months from the date of receipt when supplied in liquid form . It is crucial to protect fluorophore-conjugated antibodies from light exposure to prevent photobleaching, which can compromise detection sensitivity . Additionally, it's important to note that these antibodies should not be frozen, as freezing can damage the conjugate and reduce antibody functionality . When working with these reagents, minimize exposure to light and maintain appropriate temperature conditions throughout handling.

What are the common applications for IRF3 antibodies in research?

IRF3 antibodies are utilized across multiple research applications including:

• Flow cytometry for detection of IRF3 expression in cell populations

• Western blotting to assess IRF3 expression levels and phosphorylation status

• Immunofluorescence microscopy to visualize IRF3 nuclear translocation

• Immunoprecipitation to study IRF3 protein interactions

• Chromatin immunoprecipitation (ChIP) to analyze IRF3 binding to target gene promoters

For flow cytometry applications specifically, researchers should optimize antibody dilutions for each experimental system, as recommended by manufacturers . IRF3 antibodies are particularly valuable for studying viral infection responses, as demonstrated in research investigating cGAS-STING pathway triggering in human plasmacytoid dendritic cells .

How can I monitor IRF3 phosphorylation-dependent activation with high resolution?

Monitoring IRF3 phosphorylation requires specialized techniques beyond standard western blotting. A high-resolution approach involves using phospho-specific antibodies that recognize specific phosphorylated residues (particularly in the amino acid 395-407 region) critical for IRF3 activation . For optimal resolution, researchers should:

• Use Phos-tag™ SDS-PAGE gels that specifically retard the migration of phosphorylated proteins

• Employ short gel running times with low voltage to achieve maximum separation of phosphorylated species

• Include appropriate controls (phosphatase-treated samples) to confirm phosphorylation-specific bands

• Combine with subcellular fractionation to track nuclear translocation concurrently with phosphorylation

This approach allows researchers to distinguish between different phosphorylation states and correlate them with functional outcomes, providing insights into the kinetics and regulation of IRF3 activation during viral infection or other stimuli .

What are the technical considerations when using IRF3 antibodies for detecting different IRF3 splice variants?

When studying IRF3 splice variants, researchers must carefully select antibodies based on their epitope recognition sites. Human IRF3 may exist in multiple splice forms, including:

• A variant with deletion of amino acids 201-327

• A variant with both the above deletion plus an alternate start site at Met147

• A variant with a 125 amino acid substitution for the C-terminal 100 amino acids (328-427)

To detect specific splice variants:

• Choose antibodies with epitopes in conserved regions for detecting all variants

• Select antibodies targeting unique regions for splice variant discrimination

• Validate antibody specificity using overexpression systems with known splice variants

• Consider using RT-PCR in parallel to confirm the presence of specific splice variants at the mRNA level

Western blotting with gradient gels (8-12%) can help resolve the different molecular weight variants. For antibodies targeting epitopes in the 206-427 region, cross-reactivity with mouse and pig IRF3 should be considered, as human IRF3 shares 76% and 83% amino acid identity with these species in this region, respectively .

How can IRF3 antibodies be used in combination with cGAS-STING pathway analysis?

The cGAS-STING pathway intersects with IRF3 signaling during viral infections and cellular stress responses. For comprehensive analysis of this pathway using IRF3 antibodies:

• Use phospho-specific IRF3 antibodies to monitor activation downstream of STING signaling

• Combine with antibodies against phosphorylated TBK1, which acts as the direct kinase for IRF3

• Perform co-immunoprecipitation studies using IRF3 antibodies to identify interaction partners in the pathway

• Apply time-course studies with both STING and IRF3 antibodies to determine signaling kinetics

Recent research has shown that triggering of the cGAS-STING pathway in human plasmacytoid dendritic cells inhibits TLR9-mediated IFN production, highlighting the complex regulation between these pathways . When designing these experiments, consider that STING activation may result in different IRF3 phosphorylation patterns compared to direct viral sensing pathways, necessitating careful selection of phospho-specific antibodies.

What approaches can resolve contradictory results when using different IRF3 antibody clones?

When facing contradictory results with different IRF3 antibody clones, implement a systematic troubleshooting approach:

• Epitope mapping comparison: Determine the exact epitope recognition sites of each antibody clone. Antibodies recognizing different domains may yield different results based on protein conformation or post-translational modifications.

• Validation using multiple techniques: Confirm findings using complementary methods:

  • Flow cytometry for single-cell analysis

  • Western blotting for size verification

  • Immunoprecipitation followed by mass spectrometry for identity confirmation

  • Knockdown/knockout controls to verify specificity

• Cross-reactivity assessment: Test antibodies against related IRF family members, particularly IRF7, which shares structural similarities with IRF3.

• Functional correlation: Correlate antibody detection with functional readouts such as IFN-β promoter activity or IRF3-dependent gene expression.

Different antibody clones may detect distinct conformational states or post-translationally modified forms of IRF3, potentially explaining discrepancies in experimental results.

What are the optimal fixation and permeabilization conditions for intracellular IRF3 detection?

For optimal intracellular IRF3 detection by flow cytometry or immunofluorescence microscopy, specific fixation and permeabilization conditions are critical:

• Fixation: Use a flow cytometry-specific fixation buffer to maintain cellular architecture while enabling antibody access. For IRF3 detection in Daudi cells, Flow Cytometry Fixation Buffer has been validated for effective results .

• Permeabilization: Follow fixation with Flow Cytometry Permeabilization/Wash Buffer I to create pores in cellular membranes while preserving epitope integrity . The permeabilization step is crucial for allowing antibody access to intracellular IRF3.

• Timing considerations:

  • Fix cells immediately after stimulation to capture transient phosphorylation states

  • Limit fixation time to prevent over-fixation that may mask epitopes

  • Ensure complete permeabilization before antibody addition

• Buffer compatibility:

  • Avoid buffers containing phosphatase inhibitors when using phospho-specific antibodies

  • Ensure pH compatibility between fixatives and antibody working conditions

These optimized conditions enable reliable detection of both total and phosphorylated IRF3 in various experimental settings.

What controls should be included when using IRF3 antibodies in flow cytometry?

When using IRF3 antibodies for flow cytometry, include these essential controls:

• Isotype control: Include an isotype-matched control antibody (e.g., Catalog # IC0041G for Mouse Anti-Human IRF3 Alexa Fluor® 488-conjugated Monoclonal Antibody) to establish background staining levels and set appropriate gates .

• Positive control: Use a cell line known to express IRF3, such as Daudi human Burkitt's lymphoma cells .

• Stimulation controls:

  • Unstimulated cells to establish baseline IRF3 levels

  • Cells treated with known IRF3 activators (e.g., poly(I:C)) to confirm antibody detection of activated/phosphorylated IRF3

• Fluorescence minus one (FMO) controls: Include all fluorochromes except IRF3 antibody to account for spectral overlap.

• IRF3 knockdown/knockout controls: When available, include cells with reduced or absent IRF3 expression to verify antibody specificity.

These controls allow for accurate interpretation of flow cytometry data and ensure reliable assessment of IRF3 expression or activation states.

How can I optimize dilutions of IRF3 antibodies for different experimental systems?

Optimizing IRF3 antibody dilutions is essential for achieving the best signal-to-noise ratio in various experimental systems:

• Initial titration experiment:

  • Prepare serial dilutions of antibody (typically 1:10, 1:50, 1:100, 1:500, 1:1000)

  • Test each dilution on identical samples

  • Select the dilution that provides maximum specific signal with minimal background

• System-specific considerations:

  • Flow cytometry: Optimal dilutions should be determined by each laboratory for each application

  • Western blotting: May require higher concentrations than immunofluorescence

  • ELISA: Often requires more dilute antibody solutions

• Cell type adjustments:

  • Primary cells may require different dilutions than cell lines

  • Tissues with high endogenous peroxidase activity may need additional blocking steps

• Signal amplification options:

  • Consider biotin-streptavidin systems for low-abundance targets

  • Tyramide signal amplification can enhance sensitivity for immunohistochemistry

Document optimized conditions in laboratory protocols to ensure experimental reproducibility across studies.

Why might I observe inconsistent IRF3 nuclear translocation in stimulated cells?

Inconsistent IRF3 nuclear translocation in stimulated cells may result from several factors:

• Cell heterogeneity: Individual cells within a population may respond differently to stimulation based on cell cycle stage, receptor expression levels, or metabolic state.

• Stimulation kinetics: IRF3 nuclear translocation is transient and time-dependent. Inconsistent results may reflect:

  • Suboptimal stimulation timing

  • Asynchronous cell responses

  • Rapid nuclear-cytoplasmic shuttling due to the nuclear export signal (amino acids 139-149)

• Technical considerations:

  • Inadequate fixation allowing redistribution of IRF3 during processing

  • Suboptimal permeabilization affecting antibody access

  • Cross-reactivity with other IRF family members

• Negative regulatory mechanisms: Cell-specific differences in phosphatases or negative regulators may affect IRF3 activation persistence.

To improve consistency, perform careful time-course experiments, optimize fixation immediately after stimulation, and consider single-cell analytical approaches like imaging flow cytometry to correlate IRF3 localization with cellular activation markers.

How can I differentiate between IRF3 phosphorylation states using antibody-based detection?

Differentiating between IRF3 phosphorylation states requires specialized approaches:

• Phospho-specific antibodies: Use antibodies that specifically recognize phosphorylated serine residues in the C-terminal region (amino acids 395-407), which are critical for IRF3 activation .

• Mobility shift assays:

  • Standard SDS-PAGE can detect gross mobility shifts of hyperphosphorylated IRF3

  • Phos-tag™ acrylamide gels provide enhanced resolution of phosphorylated species

  • Include lambda phosphatase-treated controls to confirm phosphorylation-dependent shifts

• 2D gel electrophoresis: Separate IRF3 by isoelectric point in the first dimension followed by molecular weight in the second dimension to resolve different phosphorylation states.

• Sequential immunoprecipitation: Use phospho-specific antibodies for immunoprecipitation followed by detection with total IRF3 antibodies.

When interpreting results, consider that IRF3 activation involves sequential phosphorylation at multiple sites, with specific combinations determining functional outcomes. Phosphorylation at serines 396 and 398 generally correlates most strongly with transcriptional activity.

What strategies can address weak or absent signal when detecting IRF3 in primary cells?

When facing weak or absent IRF3 signals in primary cells, implement these strategies:

• Optimize cell preparation:

  • Minimize time between isolation and fixation

  • Use gentle isolation methods to preserve cellular integrity

  • Consider ex vivo stimulation to increase IRF3 levels before analysis

• Signal amplification techniques:

  • Use tyramide signal amplification for immunofluorescence

  • Employ more sensitive detection systems (e.g., chemiluminescence for Western blots)

  • Consider biotin-streptavidin amplification systems

• Antibody optimization:

  • Test multiple antibody clones targeting different epitopes

  • Reduce antibody dilution while monitoring background

  • Extend primary antibody incubation time (overnight at 4°C)

• Enhance protein extraction:

  • Use optimized lysis buffers with appropriate detergents

  • Include protease and phosphatase inhibitors to prevent degradation

  • Consider ultrasonic homogenization for difficult samples

• Concentration techniques:

  • Immunoprecipitate IRF3 before detection

  • Pool multiple samples if cell numbers are limiting

These approaches can significantly improve detection sensitivity when working with primary cells where IRF3 expression may be lower or more variable than in established cell lines.

How can computational antibody design improve IRF3 epitope-specific antibody development?

Computational antibody design represents a revolutionary approach for developing epitope-specific IRF3 antibodies:

• Generative protein design systems: New systems like JAM can generate antibodies de novo in various formats (VHH, scFv, mAb) with precise epitope targeting without experimental optimization .

• Advantages for IRF3 research:

  • Generation of antibodies against specific phosphorylation sites

  • Design of conformation-specific antibodies to distinguish active vs. inactive IRF3

  • Creation of antibodies that distinguish between IRF3 splice variants

• Practical implementation:

  • The process from computational design to recombinant characterization requires <6 weeks

  • Multiple targets can be pursued in parallel with minimal experimental overhead

  • Initial screening can be performed using yeast display libraries followed by recombinant production

• Iterative improvement:

  • Test-time computation scaling through iterative introspection can dramatically improve binding success rates and affinities

  • Each round of computation allows the design system to refine its outputs, potentially leading to 8-fold increases in binding affinity

This approach could transform IRF3 research by providing highly specific antibody tools for dissecting complex signaling pathways with unprecedented precision.

What are the considerations for using high dilution indirect immunofluorescence for IRF3 detection?

Recent research suggests higher dilution levels in indirect immunofluorescence (IIF) may improve specificity in autoantibody detection . When applying this principle to IRF3 detection:

• Dilution optimization:

  • Traditional IIF typically uses 1/80 dilutions for screening

  • Higher dilutions (≥1/640) may improve specificity for certain antibody types

  • For IRF3 antibodies, a dilution series (1/80, 1/320, 1/640) should be tested to determine optimal signal-to-noise ratio

• Validation approach:

  • Compare results between different dilution levels

  • Confirm specificity using complementary techniques (immunoblotting, ELISA)

  • Include appropriate positive and negative controls at each dilution

• Interpretation considerations:

  • Higher dilutions may reduce false positives but could miss low-affinity interactions

  • Different dilution levels may reveal distinct binding patterns

  • Correspondence analysis can help establish significant associations between dilution levels and binding patterns

• Documentation requirements:

  • Record both the pattern and intensity at each dilution

  • Document the exact fixation and permeabilization conditions used

  • Note cell type-specific differences in staining patterns

This approach can be particularly valuable when distinguishing between specific IRF3 staining and background or cross-reactivity in complex samples.

How can I integrate IRF3 antibody detection with analysis of the cGAS-STING pathway in immune cells?

The integration of IRF3 antibody detection with cGAS-STING pathway analysis offers valuable insights into innate immune signaling:

• Multiplex immunofluorescence approach:

  • Co-stain for IRF3 and STING pathway components (cGAS, STING, TBK1)

  • Use confocal microscopy to assess co-localization during activation

  • Employ spectrally distinct fluorophores to minimize bleed-through

• Pathway-specific stimulation:

  • Compare IRF3 activation patterns after stimulation with STING agonists versus direct TLR activators

  • Research indicates that triggering the cGAS-STING pathway in human plasmacytoid dendritic cells inhibits TLR9-mediated IFN production

  • This suggests complex cross-regulation between pathways converging on IRF3

• Sequential inhibition studies:

  • Use pathway-specific inhibitors to dissect the contribution of each signaling component

  • Monitor IRF3 phosphorylation and nuclear translocation as readouts

  • Correlate with downstream gene expression changes

• Single-cell analysis:

  • Combine IRF3 antibody staining with single-cell RNA-seq to correlate IRF3 activation state with transcriptional profiles

  • Mass cytometry (CyTOF) can simultaneously measure multiple phospho-proteins in the pathway

  • Imaging flow cytometry captures both localization and activation markers

This integrated approach can reveal novel insights into how different innate immune pathways cooperate or antagonize each other through IRF3-dependent mechanisms.

What emerging technologies might enhance IRF3 antibody applications in the next five years?

The landscape for IRF3 antibody applications is likely to evolve significantly with several emerging technologies:

• Computational antibody design advancement: Systems like JAM demonstrate the potential for fully computational design of antibodies with therapeutic-grade properties, including sub-nanomolar affinities . This approach could yield highly specific IRF3 antibodies targeting precise epitopes or conformational states.

• Single-cell spatial proteomics: New multiplexed imaging techniques will allow visualization of IRF3 activation in the context of other signaling molecules, creating spatial maps of innate immune responses at single-cell resolution.

• Nanobody and single-domain antibody platforms: These smaller antibody formats may offer improved access to hidden epitopes and better penetration for live-cell imaging of IRF3 dynamics.

• Optogenetic antibody reporting systems: Fusion of photoactivatable domains to antibody-based sensors could allow real-time visualization of IRF3 activation with minimal cellular perturbation.

• CRISPR-based tagging: Direct labeling of endogenous IRF3 using CRISPR-mediated knock-in of fluorescent or epitope tags will enable study of IRF3 at physiological expression levels.

These technologies will collectively enhance our ability to study IRF3 with improved temporal and spatial resolution, advancing our understanding of innate immune signaling dynamics.

How might comparative analysis of IRF3 across species benefit from antibody-based approaches?

Comparative analysis of IRF3 across species can benefit substantially from carefully selected antibody approaches:

• Cross-reactivity considerations: Human IRF3 shares 76% amino acid identity with mouse IRF3 and 83% with pig IRF3 in the region spanning amino acids 206-427 . This knowledge can guide selection of antibodies for cross-species studies.

• Conserved epitope targeting:

  • Antibodies targeting highly conserved domains (e.g., DNA-binding domain) may work across multiple species

  • Domain-specific antibodies can compare functional differences in specific regions

• Evolutionary insights:

  • Antibody panels detecting species-specific modifications can reveal evolutionary adaptations in IRF3 regulation

  • Phosphorylation-specific antibodies may identify conserved or divergent activation mechanisms

• Translational applications:

  • Identifying functionally equivalent epitopes across species enhances translatability of animal models

  • Antibodies validated across multiple species facilitate comparative studies of viral evasion mechanisms

This comparative approach could reveal fundamental aspects of IRF3 biology conserved throughout evolution versus species-specific adaptations, enhancing our understanding of innate immunity across different organisms.